EUSA Erwinaze approval shows major pharma how to win in orphan markets, says CEO
This article was originally published in Scrip
Executive Summary
In what the company is calling a transformative event, EUSA Pharma, a specialty pharmaceutical company focused on oncology, announced that the US FDA has approved its orphan drug Erwinaze (asparaginase Erwinia chrysanthemi) for the treatment of acute lymphoblastic leukaemia in patients with hypersensitivity to E. coli-derived asparaginase.